梅斯医学专访王长谦副院长:常见冠心病的诊断治疗

2016-07-25 MedSci MedSci原创

    冠心病是冠状动脉粥样硬化性心脏病的简称,也成缺血性心脏病,包括心绞痛、心率失常,急性心肌梗塞,心力衰竭和心脏骤停等,发病率高,风险大,相应的死亡率也高。冠心病通常是一种进展性疾病,平时可以没有任何症状,但随着时间的转移,病变和病情可能会逐渐地加重,其危害不容小觑。那么,我们来看看对于刚刚手术完的两例患者上海交通大学医学院附属第九人民医院的王长谦副院长有怎么样的看法呢?

冠心病是冠状动脉粥样硬化性心脏病的简称,也成缺血性心脏病,包括心绞痛、心率失常,急性心肌梗塞,心力衰竭和心脏骤停等,发病率高,风险大,相应的死亡率也高。冠心病通常是一种进展性疾病,平时可以没有任何症状,但随着时间的转移,病变和病情可能会逐渐地加重,其危害不容小觑。那么,我们来看看对于刚刚手术完的两例患者上海交通大学医学院附属第九人民医院的王长谦副院长有怎么样的看法呢?

对于怀疑冠心病的患者,会让患者去做一个平板运动的试验,根据试验结果来给出正确的评价,对于由于当日手术的患者饮食不是很好,无法进行测试,直接做了一个造影,画面显示结果没有严重的问题,第二例患者主要是一个不稳定心绞痛,外面做了一个冠状动脉CTA 冠状动脉CTA 提示左侧冠状动脉前降支、回旋支有动脉造影斑块,但右侧的冠状动脉中段显示不是很清楚,病人症状还是比较典型,虽然心肌损伤标志物没有升高,初发心绞痛,从冠脉CTA上来看,右冠中段病变可疑的,所以做了冠脉造影提示右冠中段有个很长的弥漫性严重狭窄,最重的地方达到90%,我们做给病人做了一些干预,放了一个冠状动脉支架。

   专家介绍

      

王长谦教授,主任医师,心血管内科主任,九院临床医学院副院长,诊断学教研室主任等。医学博士,博士研究生导师。长期致力于心血管疾病的临床、科研和教学工作。临床擅长动脉粥样硬化、冠心病的防治及冠心病、心肌梗塞的介入治疗。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703221, encodeId=e29f1e03221a6, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 18 03:35:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035104, encodeId=cfa320351043c, content=<a href='/topic/show?id=faa0683683b' target=_blank style='color:#2F92EE;'>#王长谦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68368, encryptionId=faa0683683b, topicName=王长谦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Mar 02 16:35:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033418, encodeId=d14f2033418a9, content=<a href='/topic/show?id=8e6532e9732' target=_blank style='color:#2F92EE;'>#副院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32797, encryptionId=8e6532e9732, topicName=副院长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Oct 10 02:35:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276835, encodeId=260112e68356b, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423621, encodeId=8de7142362198, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703221, encodeId=e29f1e03221a6, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 18 03:35:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035104, encodeId=cfa320351043c, content=<a href='/topic/show?id=faa0683683b' target=_blank style='color:#2F92EE;'>#王长谦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68368, encryptionId=faa0683683b, topicName=王长谦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Mar 02 16:35:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033418, encodeId=d14f2033418a9, content=<a href='/topic/show?id=8e6532e9732' target=_blank style='color:#2F92EE;'>#副院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32797, encryptionId=8e6532e9732, topicName=副院长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Oct 10 02:35:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276835, encodeId=260112e68356b, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423621, encodeId=8de7142362198, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703221, encodeId=e29f1e03221a6, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 18 03:35:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035104, encodeId=cfa320351043c, content=<a href='/topic/show?id=faa0683683b' target=_blank style='color:#2F92EE;'>#王长谦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68368, encryptionId=faa0683683b, topicName=王长谦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Mar 02 16:35:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033418, encodeId=d14f2033418a9, content=<a href='/topic/show?id=8e6532e9732' target=_blank style='color:#2F92EE;'>#副院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32797, encryptionId=8e6532e9732, topicName=副院长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Oct 10 02:35:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276835, encodeId=260112e68356b, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423621, encodeId=8de7142362198, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2016-10-10 xugumin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703221, encodeId=e29f1e03221a6, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 18 03:35:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035104, encodeId=cfa320351043c, content=<a href='/topic/show?id=faa0683683b' target=_blank style='color:#2F92EE;'>#王长谦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68368, encryptionId=faa0683683b, topicName=王长谦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Mar 02 16:35:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033418, encodeId=d14f2033418a9, content=<a href='/topic/show?id=8e6532e9732' target=_blank style='color:#2F92EE;'>#副院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32797, encryptionId=8e6532e9732, topicName=副院长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Oct 10 02:35:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276835, encodeId=260112e68356b, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423621, encodeId=8de7142362198, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2016-07-27 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1703221, encodeId=e29f1e03221a6, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 18 03:35:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035104, encodeId=cfa320351043c, content=<a href='/topic/show?id=faa0683683b' target=_blank style='color:#2F92EE;'>#王长谦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68368, encryptionId=faa0683683b, topicName=王长谦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Mar 02 16:35:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033418, encodeId=d14f2033418a9, content=<a href='/topic/show?id=8e6532e9732' target=_blank style='color:#2F92EE;'>#副院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32797, encryptionId=8e6532e9732, topicName=副院长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Oct 10 02:35:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276835, encodeId=260112e68356b, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423621, encodeId=8de7142362198, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Wed Jul 27 05:35:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]

相关资讯

Int J Cardiol:非高密度脂蛋白胆固醇与冠心病的死亡率相关

背景:非高密度脂蛋白(HDL)的胆固醇水平,一般不受空腹状态或血清甘油三酯水平的影响,可能有助于预测未来的心血管事件。本研究旨在探讨一般日本人群中,非高密度脂蛋白胆固醇在致命性冠状动脉事件和卒中的发展中的作用。方法:从NIPPON DATA 90个前瞻性队列研究中,从1990对8383名受试者随访20年。排除无血脂或协变量数据者666例,561例75岁以上,274例心血管疾病史,181例有降脂治疗

Stroke:缺血性卒中和冠心病史患者的颈动脉斑块特征研究

背景:由于动脉粥样硬化是一种全身性疾病,1个位置上存在和组成可能与远端缺血事件有关。研究者探讨颈动脉粥样硬化壁厚,狭窄,斑块组成是否与缺血性卒中和冠状动脉心脏病(CHD)相关。方法:以人口为基础的鹿特丹研究,1731无症状的参与者(平均年龄为72.4±9.1岁, 55%为男性)进行了双侧颈动脉磁共振成像。研究者评估颈动脉壁厚度、狭窄和斑块组成,斑块内出血,脂质和钙化。磁共振成像后,对缺血性卒中和冠

JAMA Intern Med:补充鱼油能降低致命性冠心病风险

近期有荟萃分析结果表明,植物性和海鲜性ω-3脂肪酸的生物标志物浓度与致命性冠心病(CHD)风险的降低有关。斯坦福大学医学院的博士后研究人员Liana C. Del Gobbo对来自16个国家涉及45637名参与者的19项研究进行了荟萃分析。其中前瞻性队列研究有10项,前瞻性嵌套病例对照研究有7项,回顾性病例对照研究有2项。这些研究中的生物标志物类型的测定包括磷脂(血浆或红细胞,N = 10)、总血

重点概要:冠心病合理用药指南(附全文下载)

冠状动脉粥样硬化性心脏病是指由于 冠状动脉粥样硬化使管腔狭窄、痉挛或阻塞导致心 肌缺血、缺氧或坏死而引发的心脏病,统称为冠状 动脉性心脏病或冠状动脉疾病,简称冠心病,归属 为缺血性心脏病,是动脉粥样硬化导致器官病变的 最常见类型。我国冠心病流行情况 根据最新发布的《中 国心血管病报告 2014》显示,我国心血管疾病流 行趋势明显,导致心血管疾病发病人数增加。总体 上看,我国心血管疾病患病率及死

必知:冠心病&脑卒中发作的十大讯息

你可能知道有的人–你的家人或朋友–曾经有过冠心病发作或脑卒中 (一种脑部疾病发作)。这些心血管疾病(心脏和血管的疾病)正在使全世界愈来愈多的人死亡,富人和穷人都不能幸免。 那些经历过冠心病发作或脑卒中的人即便能够存活,也需要接受长期的药物治疗。 如果你自己经历过冠心病发作或脑卒中,或者护理过这样的病人,你就会了解这些疾病对病人及其家庭的生活造成多么严重的影响,这种影响甚至可以从家庭延伸到社会。但是

J Heart Lung Transplant:冠心病患者移植后的长期生存优于非冠心病患者??

背景:充血性心脏疾病(CHD)成人移植受者的死亡率和发病率的研究是有限的。研究者进行系统的回顾和荟萃分析比较2个群体的移植后的预后。方法:进行电子数据库搜索后,研究者选择评估冠心病与非冠心病患者,死亡率,特定的死亡率以及再手术和透析的风险。研究者使用随机效应模型进行荟萃分析。结果:与非CHD患者相比,CHD患者30天死亡率明显升高(RR,2.18;95% CI,1.62-2.93;I2 = 41%